Elutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024
Elutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024
SILVER SPRING, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia"), a company pioneering drug-eluting biomatrix products, is excited to announce its participation in the upcoming Heart Rhythm Society's annual meeting (HRS 2024), where it will showcase its innovative CanGaroo BioEnvelope product line. Designed specifically for cardiac implantable electronic devices (CIEDs), the biologic matrix of the envelope works with the body to promote a natural healing response and enhance device stability and patient comfort. Join us at the Boston Convention & Exhibition Center from May 16-18, 2024, where Elutia will demonstrate the future of cardiac device protection at Booth #1443.
馬里蘭州銀泉，2024年5月13日（GLOBE NEWSWIRE）——開創藥物洗脫生物矩陣產品的公司Elutia Inc.（納斯達克股票代碼：ELUT）（“Elutia”）很高興地宣佈參加即將舉行的心律協會年會（HRS 2024），屆時它將展示其創新的Cangaroo 生物信封產品線。該包膜的生物基質專爲心臟植入式電子設備 (CIED) 而設計，可與人體協作，促進自然癒合反應，增強設備穩定性和患者舒適度。2024 年 5 月 16 日至 18 日，我們將在波士頓會展中心加入我們，Elutia 將在 #1443 號展位展示心臟設備保護的未來。
Elutia management attending HRS 2024 includes Dr. Randy Mills, Chief Executive Officer; Matt Ferguson, Chief Financial Officer; Dr. Michelle Williams, Chief Scientific Officer; and Dr. Kimberly Mulligan, Vice President and General Manager of Cardiovascular. Attendees interested in scheduling a meeting with management during the conference may register through the HRS 2024 meeting portal here or contact ir@elutia.com.
參加HRS 2024的Elutia管理層包括首席執行官蘭迪·米爾斯博士、首席財務官馬特·弗格森、首席科學官米歇爾·威廉姆斯博士和心血管副總裁兼總經理金伯利·穆里根博士。有興趣在會議期間安排與管理層會面的與會者可以在此處通過HRS 2024會議門戶網站註冊或聯繫 ir@elutia.com。
The CanGaroo BioEnvelope comprises an acellular biologic matrix that promotes a biologic healing response at the interface between the CIED and the patient. This enhances patient outcomes by minimizing inflammation and promoting the stimulation of healthy, vascularized tissue. Designed for use in patients with pacemakers and internal defibrillators, CanGaroo is clinically proven to reduce post-surgical device implantation complications.
CangaRoo BioEnvelope 由一種無細胞生物基質組成，可促進 CIED 與患者交界處的生物治療反應。這可以通過最大限度地減少炎症和促進對健康血管化組織的刺激來增強患者的預後。CangaRoo專爲使用起搏器和內部除顫器的患者而設計，經臨床證明可減少術後設備植入併發症。
About Elutia
關於 Elutia
Elutia develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia's mission is humanizing medicine so patients can thrive without compromise. For more information, visit .
Elutia 開發和商業化生物製劑，以改善醫療器械與需要它們的患者之間的兼容性。隨着越來越多的人口需要植入式技術，Elutia的使命是實現醫學人性化，使患者能夠毫不妥協地茁壯成長。欲了解更多信息，請訪問。
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
投資者：
馬特·斯坦伯格
FINN 合作伙伴
matt.steinberg@finnpartners.com
譯文內容由第三人軟體翻譯。